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NADPH oxidases (Nox) are a primary source of reac-
tive oxygen species (ROS), which function in normal
physiology and, when overproduced, in pathophysi-
ology. Recent studies using mice deficient in Nox2
identify this isoform as a novel target against Nox2-
implicated inflammatory diseases. Nox2 activation
depends on the binding of the proline-rich domain of
its heterodimeric partner p22phox to p47phox. A
high-throughput screen that monitored this interac-
tion via fluorescence polarization identified ebselen
and several of its analogs as inhibitors. Medicinal
chemistrywasperformed toexplore structure-activity
relationships and to optimize potency. Ebselen and
analogs potently inhibited Nox1 and Nox2 activity
but were less effective against other isoforms.
Ebselen also blocked translocation of p47phox to
neutrophil membranes. Thus, ebselen and its analogs
represent a class of compounds that inhibit ROS
generation by interrupting the assembly of Nox2-
activating regulatory subunits.
INTRODUCTION
Reactive oxygen species (ROS) play important roles in physio-
logic functions including host defense and signal transduction,
and can also cause ‘‘oxidative stress,’’ which plays a central
role in inflammation, tissue damage, abnormal cell growth, and
fibrosis associated with a variety of diseases. Recent reviews
catalog the role of oxidative stress in acute and chronic diseases
that involve the cardiovascular, nervous, endocrine, respiratory,
and excretory systems (Kashihara et al., 2010; Essick and Sam,
2010; Park et al., 2009; Fatokun et al., 2008; Elahi et al., 2009).
While mitochondria and various metabolic enzymes were origi-
nally considered to be the sources of ROS in disease, NADPH
oxidases (Nox and Duox enzymes) have more recently been
recognized as the major source of ROS in many cells and in
a multitude of disease states (reviewed in Lambeth et al., 2008;
Lambeth, 2007). Rather than generating ROS as minor byprod-752 Chemistry & Biology 19, 752–763, June 22, 2012 ª2012 Elsevieructs of metabolism, Nox enzymes catalyze NADPH-dependent
generation of superoxide or hydrogen peroxide as their sole
function and with high catalytic efficiencies, e.g., up to
5,000 mol O2./mol heme /per minute for Nox2 (Paclet et al.,
2007). Secondary metabolites such as hydroxyl radical and, in
the presence of myeloperoxidase, hypochlorous acid can also
be formed, particularly in inflamed tissues where they contribute
to molecular and cellular damage (Vignais, 2002).
Nox enzymes are a family of seven transmembrane catalytic
moieties (Nox1, Nox2, Nox3, Nox4, Nox5, Duox1, and Duox2)
(Suh et al., 1999; Lambeth, 2004; Lambeth et al., 2000; Geiszt
et al., 2000; Cheng et al., 2001; Shiose et al., 2001; De Deken
et al., 2000; Ba´nfi et al., 2004) that show distinct tissue expres-
sion andmechanisms of regulation. Themost thoroughly studied
Nox isoform is Nox2, also known as the ‘‘phagocyte NADPH
oxidase’’ or ‘‘respiratory burst oxidase.’’ Nox2 generates super-
oxide, as do Nox1, 3, and 5, while Nox4, Duox1, and Duox2
produce mainly hydrogen peroxide (Takac et al., 2011). The
phagocyte NADPH oxidase is inactive in unstimulated neu-
trophils, but becomes activated upon exposure to microbes,
microbial products, and inflammatory mediators. Nox2 forms
a heterodimer with the small membrane subunit p22phox, the
C-terminal proline-rich domain (PRD) of which provides a dock-
ing site for p47phox directly, and indirectly for other regulatory
subunits of the complex (p67phox, p40phox, and Rac1). This
interaction is an early and key step in an intricate series of
protein-protein interactions that result in enzyme activation. Trig-
gered by phosphorylation of p47phox,which unmasks a bis-SH3
domain present in p47phox, the regulatory subunits translocate
from the cytosol to the membrane, where the bis-SH3 moiety
binds to the PRD of p22phox (Sumimoto et al., 1994; Leusen
et al., 1994; Leto et al., 1994; Vignais, 2002; Lambeth et al.,
2007; Babior et al., 2002). This interaction is essential for the
activity of the Nox2 system because mutations that disrupt this
binding prevent superoxide generation (Kawahara et al., 2005;
Sumimoto et al., 1996; de Mendez et al., 1997). An analogous
binding interaction between the same PRD of p22phox and the
highly homologous bis-SH3 domain of the regulatory subunit
NOXO1 activates Nox1 and Nox3 (Ba´nfi et al., 2003, 2004).
Nox4 also requires p22phox for activity, but the PRD of
p22phox is not needed because Nox4 is constitutively active
and independent of activating subunits (Kawahara et al., 2005).Ltd All rights reserved
Figure 1. Fluorescence Polarization Assesses Binding of p22-PRD
Peptide to p47 bis-SH3 Domain
(A) FP in mP units of 10 nM of synthetic, rhodamine-labeled peptide corre-
sponding to the PRD of p22phox (rho-PRD) was measured in the presence of
increasing concentrations of recombinant GST-p47-bis-SH3 (filled squares) or
GST (open squares) as described in Experimental Procedures. Points repre-
sent means of triplicate measurements, and were fit (R2 = 0.99) to a dose
response model using nonlinear least-squares fit as described in Experimental
Procedures. The Kd for binding of the peptide to p47-bis-SH3 in this experi-
ment was calculated to be 20 nM.
(B) FP of 10 nM rho-PRD in the presence of 20 nM p47-bis-SH3 and increasing
concentrations of recombinant MBP-p22-C protein (filled squares) or recom-
binant MBP alone (open squares) were measured as described in Experi-
mental Procedures. Points represent means of triplicate measurements and
were fit (R2 = 0.94) to a one-site competition model as detailed in Experimental
Procedures, yielding an IC50 for MBP-p22-C of 120 nM and a Ki of 60 nM. This
experiment is representative of at least three independent experiments.
Figure S1 shows the results of a pull-down experiment that supports this
figure.
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Ebselen Blocks Nox2 Assembly and ROS ProductionNox5 andDuox1-2 do not require p22phox for activity (Kawahara
et al., 2005, 2011; Luxen et al., 2009; Grasberger and Refetoff,
2006).
Animal models of various diseases, including studies using
Nox isoform-deleted strains of mice, demonstrate a protective
role of inhibiting or deleting these enzymes, implicating Nox
isoenzyme forms as novel targets for the development of drugs.
Conditions in which Nox enzymes have been implicated include
hypertension (Nox1) (Matsuno et al., 2005; Lasse`gue et al.,
2001; Gavazzi et al., 2006), diabetic nephropathy (Nox4) (Gorin
et al., 2005; Sedeek et al., 2010), lung fibrosis (Nox4) (Hecker
et al., 2009; Carnesecchi et al., 2011), acute lung inflammation
(Nox2) (Snelgrove et al., 2006; Imai et al., 2008), Alzheimer
disease (Park et al., 2008), traumatic brain injury (Nox2) (Dohi
et al., 2010), and others (e.g., see Lambeth, 2007; Jaquet
et al., 2009). Because Nox2 is particularly important in many
diseases that have an inflammatory component (Lambeth,
2007), it represents a promising target for drug development
for these conditions.
The status of development of drugs/inhibitors targeting Nox
enzymes has been reviewed recently (Lambeth et al., 2008;
Jaquet et al., 2009). Most existing inhibitors are nonselective
and/or have properties that preclude their development as
drugs. A Nox1 and Nox4-selective inhibitor was recently re-
ported (Laleu et al., 2010) and another report identified a Nox1-
selective inhibitor (Gianni et al., 2010). The present studies
were undertaken to identify inhibitors that are selective for
Nox2. A fluorescence polarization (FP) assay was developed to
identify inhibitors that block the interaction of the bis-SH3
domain of p47phox with the PRD of p22phox. The assay was
used to carry out a high-throughput screen (HTS) to identify
potential inhibitors of Nox2. Surprisingly, among the hits were
the selenium-containing analog ebselen and several of its close
analogs including those in which sulfur replaces selenium.
Ebselen was previously characterized as a glutathione peroxi-
dase mimetic (Sies, 1993, 1995; Parnham et al., 1991; Parnham,
1990; Schewe, 1995; Parnham and Sies, 2000). According to this
mechanism, ebselen and its selenium- (but not sulfur-) contain-
ing analogs are able to consume hydrogen peroxide in a catalytic
cycle that uses thiol-containing compounds such as glutathione
as a substrate. The present studies demonstrate, to our knowl-
edge, a new mode of action for this class of molecules as
Nox2 inhibitors that directly target assembly of the Nox2 regula-
tory subunits.
RESULTS
Design of a High-Throughput Screening Assay
As described previously, activation of Nox2 in vivo depends on
the binding of p47phox to p22phox (Vignais, 2002; Lambeth
et al., 2007; Babior et al., 2002), which is mediated by binding
of the PRD of p22phox to a deep binding pocket formed at the
interface between the two SH3 domains that together comprise
the single functional bis-SH3 domain of p47phox (Sumimoto
et al., 1996; Groemping et al., 2003). Using the expressed, puri-
fied protein in which glutathione S-transferase (GST) is fused to
the bis-SH3 domain of p47phox (residues 156–285, referred to
as GST-p47-bis-SH3), a FP assay was developed to measure
the binding of a synthetic, rhodamine-labeled peptide corre-Chemistry & Biology 19,sponding to the PRD of p22phox (rho-PRD). GST-p47-bis-SH3
lacks the auto-inhibitory region and thus does not require phos-
phorylation to bind the PRD. At a constant rho-PRD con-
centration, increasing GST-p47-bis-SH3 produced a saturable
increase in polarization (Figure 1A), corresponding in several
experiments to a Kd of 20–40 nM. GST alone had no effect on
FP (Figure 1A). Using rho-PRD peptide bound to the GST-p47-
bis-SH3, we tested whether a maltose-binding protein (MBP)
fusion protein linked to the entire C-terminal region of p22phox
(residues 132–195, which includes the PRD, and which we call
MBP-p22-C), could displace rho-PRD from its binding site on
the bis-SH3 domain, which would result in decreased FP. Fig-
ure 1B demonstrates that MBP-p22-C but not MBP alone752–763, June 22, 2012 ª2012 Elsevier Ltd All rights reserved 753
Figure 2. Hits fromHTS Inhibit both Binding
of rho-PRD to GST-p47-bis-SH3 and Nox2
Activity
Structures of ebselen (A) and Thr101 (B) are
shown. FP of 10 nM rho-PRDwasmeasured in the
presence of 30 nM GST-p47-bis-SH3 and varying
concentration of ebselen (A) or Thr101 (B) as
described in Experimental Procedures. The FP
value of rho-PRD + GST-p47-bis-SH3 + 500 nM
MBP-p22-C was normalized to 0%, while the FP
value of free rho-PRD was normalized to 100%.
Nox2 activity (in normalized luminescence units)
was measured as described in Experimental
Procedures, with the activity in 1% DMSO alone
normalized to 100%. Inhibition of Nox2 activity in
the cell-free assay by ebselen (C) and Thr101 (D) is
shown with filled circles. Control assays in which
ROS was supplied using the same detection
method by the superoxide-generating xanthine/
xanthine oxidase system in place of Nox2 were
performed (open circles) in the presence of
varying concentrations of ebselen (C) and Thr101
(D). Data points represent the means ± SD of
triplicate measurements, and were fit to a one-site
competition model as described in Experimental
Procedures. Experiments shown are representa-
tive of two to five independent determinations for
each assay.
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the binding affinity of MBP-p22-C is similar to that of the PRD
alone; the latter therefore represents the major binding determi-
nant. The kinetics of binding were monitored upon addition of
multiple concentrations of the GST-p47-bis-SH3 to rho-PRD.
Binding was complete by the time the first measurement was
made and the FP was stable over the course of more than 8 hr
(data not shown). In addition, FP and binding constants were
minimally affected by DMSO concentrations up to 1%. Thus,
the binding of rho-PRD to GST-p47-bis-SH3 is rapid, tight,
specific, and stable. We reasoned that the competition for
binding that results in a decrease in FP could be used as the
basis for a HTS for inhibitors that target the p47phox-bis-SH3
binding pocket.
High-Throughput Screening Identifies Ebselen and
Analog as Hits
We performed the FP assay adapted to a 1536- well HTS format
to screen >200,000 compounds in the MLSCN library, using
a concentration of 20 mM compound. (Details of the screen and
results have been deposited in PubChem AID: 1274 and AID:
1275 [National Center for Biotechnology Information]). The
1200 compounds that produced the greatest apparent decrease
in FP were rescreened in HTS format to obtain dose responses
and autofluorescence information. Fifty-five compounds were
chosen on the basis of (1) IC50 less than 15 mM; (2) low or no inter-
fering autofluorescence; and (3) approximately ideal dose-
response curves, the shapes of which corresponded to single
site binding. Individual dose-response curves were then re-
peated using the FP binding assay, and dose responses for inhi-
bition of Nox2-dependent ROS-generating activity were carried754 Chemistry & Biology 19, 752–763, June 22, 2012 ª2012 Elsevierout in a cell-free system that uses isolated neutrophil membranes
as a source for Nox2, plus recombinant, purified phox regulatory
subunits (Uhlinger et al., 1992). Compounds with IC50 values
greater than 10 mM or those that interfered with a control activity
assay in which superoxide was supplied via a xanthine/xanthine
oxidase system were eliminated from further consideration.
Among a small number of bona fide inhibitors was ebselen, a
previously published compound that has been characterized to
have glutathione peroxidase-like catalytic activity (Sies, 1993,
1995; Parnham et al., 1991; Parnham, 1990; Schewe, 1995;
Parnham and Sies, 2000). Ebselen showed an IC50 of 0.3 mM in
the FP binding assay and 0.6 mM in the cell-free Nox2 activity
assay (Figure 2A). The effect on the Nox2 system occurred at
much lower concentrations than the 10 mM concentration
reported for ebselen’s glutathione peroxidase activity (Mu¨ller
et al., 1984) and also its reported 17 mM IC50 for inhibition of
horseradish peroxidase (Mishra et al., 2006). Another hit com-
pound is a close analog of ebselen in which sulfur replaces sele-
nium. This compound, which we call Thr101, showed moderate
activity (IC50 = 4 mM) in both the binding and Nox2 activity assays
(Figure 2B). Interestingly, sulfur analogs of ebselen lack gluta-
thione peroxidase activity (Leurs et al., 1989). Neither compound
affected the assay system when superoxide was provided by
a xanthine/xanthine oxidase system (open circles in lower panels
of Figure 2). Additional commercially available analogs of ebse-
len were obtained and tested, and several of these also proved
to be inhibitors of Nox2 (vide infra).
Ebselen markedly inhibited the binding of purified recom-
binant MBP-p22-C and GST-p47-bis-SH3 assessed in a pull-
down assay using glutathione agarose beads (Figure S1 avail-
able online), confirming the results from the FP binding assay.Ltd All rights reserved
Figure 3. Ebselen Analogs Inhibit both Binding and Enzyme Activity
Twenty-seven analogs of ebselen that inhibited binding of rho-PRD to GST-
p47-bis-SH3 with EC50 of 10 mM or less were also tested for effects on Nox2
activity in the cell-free assay described in Experimental Procedures. Sulfur-
(black symbols) and selenium-containing (red symbols) analogs inhibit both
binding and activity; correlation coefficient R = 0.7 (p < 0.0001), R2 = 0.5; slope
significantly nonzero (p < 0.001) as determined in GraphPad Prism. Com-
pounds g, h, and i are representative examples of compounds that did not
inhibit in the binding assay and also did not inhibit in the activity assay (EC50 or
IC50 greater than 25 mM).
Structures of the compounds in this figure are presented in Table S1, and the
synthesis scheme is shown in Figure S2.
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Study
To optimize the potency of ebselen-like molecules toward the
Nox2 target, we synthesized novel analogs of this series in-
cluding both selenium- and sulfur-containing versions. Replace-
ment of selenium or sulfur with oxygen (TG4-225-2), carbon
(Thr140), nitrogen (JM3-71b, c), or sulfonamine (Thr 141) resulted
in complete loss of activity (Table S1). Likewise, replacement of
the middle five-membered ring system with benzothiazines
(TG4-182, TG4-184), benzothiazine-dione (TG4-185), or ben-
zothiazoles (NOX-AS3-1, Nox-AS3-2) also yielded inactive
compounds (Table S1). We therefore synthesized a series of
compounds that retained the central ring but varied the substit-
uents on the other two rings (Table S1).
Approximately 30 selenium and sulfur analogs were made and
tested in both the FP binding assay and the cell-free Nox2
activity assay. Figure 3 shows the correlation between EC50
values for the approximately 30 active compounds in the FP
binding assay (x axis) versus IC50 values for the same com-
pounds in the Nox2 activity assay (y axis) (R = 0.7 [p < 0.0001],
R2 = 0.5; slope significantly nonzero [p < 0.001]). An additional
15 analogs failed significantly to inhibit binding of rho-PRD to
GST-p47-bis-SH3 at concentrations up to 25 mM. Data for three
representative inactive compounds in which a carbon was
substituted for the selenium are shown (g, h, and i) in Figure 3.
The correlation points to the interruption of the p47phox
p22phox interaction as the mode of action of these both Se-
and S- containing analogs in this chemical series.
Several conclusions can be made with regard to structural
features that affect activity. For the sulfur analogs, the parentChemistry & Biology 19,compound of the sulfur-containing series, Thr101, has the
same potency in both binding and activity assays, about 4 mM
(Figure 2B). An isothiazolone analogwith a p-COOMe group (Fig-
ure 3; Table S1, l) shows 10 fold higher activity compared with
the parent compound in both the binding and cell-free activity
assays: 500 nM and 800 nM, respectively. Replacing p-COOMe
with a p-COOEt (Figure 3; Table S1, m) or a p-COOtBu (Figure 3;
Table S1, s) caused a slight decrease in potency. The p-COOnBu
group at this position proved to be even less potent than the
parent compound, with an IC50 = 10 mM in the FP assay, while
longer chains in this position failed to bind at all, suggesting
a limitation in the length of the binding cavity at this position.
Switching the methyl ester substitution from the para- to the
ortho-position resulted in a complete loss of activity. A fluoro-
derivative (Figure 3; Table S1, j) showed somewhat increased
potency compared to the parent compound with an IC50 of
1.5 mM in the activity assay, but was similar to the parent
compound in the binding assay. However, adding a second fluo-
rine substituent at the position para to sulfur in the benzoiso-
thiazolone ring (Table S1, k) improves binding by 3-fold and
activity by 5-fold making the compound nearly as effective as
ebselen itself. Replacement of the substituted phenyl ring on
the right side of the molecule with a thiozole rings (Figure 3;
Table S1, n), thiodiazole rings (Figure 3; Table S1, p, r) or pyridine
ring (Figure 3/Table S1, ε) were less effective than the p-COOMe
analog (Figure 3; Table S1, l). An isothiazolone analog (Figure 3;
Table S1, t) that lacks the phenyl-fused ring on the left side of the
molecule also has significantly decreased activity.
For the selenium-containing compounds, the parent com-
pound is ebselen (b), which has submicromolar potency in
both binding and activity assays (Figure 2A). Similar to the sulfur
series, substitution with a p-COOMe on the right-hand ring, (Fig-
ure 3; Table S1, a) modestly increases the binding potency (FP
assay) compared to the parent compound. The combination of
a fluoro-substitution on the left side ring, along with a 1,4-dioxole
ring fused to the right-hand ring (Figure 3; Table S1, w) signifi-
cantly improved the potency, while a 1,3 dioxane ring fused to
the right-hand ring (Figure 3; Table S1, d) had little effect. In
contrast either two fluorines (b) or two methoxyl groups (c) on
the left-hand ring decreased the activity about 2-fold.
Ebselen Analogs Are Selective for Nox1 and Nox2 over
Nox4
Our HTS was designed to identify inhibitors that show selectivity
for Nox2, an isoform that requires regulatory subunits for activity,
and should not inhibit Nox4, which does not require activation via
protein:protein interactions. Isolated Nox enzymes are labile
(Tamura et al., 1992), particularly when removed using deter-
gents from membranes. Therefore we tested the isoform selec-
tivity of selenium and sulfur analogs of ebselen in assays using
several cell-based systems: (1) human neutrophils, which ex-
press high levels of Nox2 but not any other Nox isoform;
(2) two HEK cell lines, one that stably expresses human Nox1
(HEK/Nox1rb) and one that stably expresses Nox4 (HEK/
Nox4rb; both stable cell lines were the generous gift of Dr. Ralf
Brandes); and (3) HEK cells transiently transfected with Nox5
(Kawahara et al., 2011) which activates via binding of its EF
hand to its dehydrogenase domain (Tirone et al., 2010). These
assays use L-012 luminescence as a reporter for superoxide752–763, June 22, 2012 ª2012 Elsevier Ltd All rights reserved 755
Figure 4. Ebselen Analogs Are Selective for Nox2 over Nox4
(A and B) Ebselen or Thr101 concentrations were varied as indicated, and
Nox2 activity was measured in intact neutrophils (filled squares) and Nox4
activity in HEK-Nox4rb cells (filled triangles) as described in Experimental
Procedures. In assay control experiments, H202 was added directly to the
assay system (open circles). In additional control experiments, the xanthine/
xanthine oxidase superoxide-generating system was used in place of ROS-
generating cells; results were similar to those shown in Figure 2, and are
omitted here for clarity. Nox activity in the presence of 1% DMSO (vehicle
control) was taken as 100% activity. Data points represent means ± SD of
triplicate measurements, and were fit to a one-site competition model as
described in Experimental Procedures. The data shown are representative of
two to four independent determinations for each assay.
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presence of horseradish peroxidase) for hydrogen peroxide (the
ROS product generated by Nox4) (Takac et al., 2011). As seen in
Figure 4 and Table 1, both selenium and sulfur analogs of
ebselen showed more than an order of magnitude selectivity
for Nox1 and Nox2 over Nox4 in intact cells, supporting the
proposed mode of action. In addition, four of five compounds
tested showed a 5-fold or greater selectivity of Nox2 over
Nox5. These compounds did not interfere with assays in which
ROS was supplied via xanthine/xanthine oxidase (Figure 3 and
Table 1) or directly as H2O2 (Figure 4 and Table 1), nor did they
affect cell viability of either neutrophils or HEK cells below
30 mM (data not shown). Except for Thr101, which showed an
IC50 around 10 mM, these compounds inhibited Nox4 in HEK
cells with IC50 values greater than 50 mM. The apparent effect
of Thr101 on Nox4 activity was indistinguishable from its effect
on the control assay in which H2O2 was supplied directly in place
of cells. Thus, the apparent inhibition of Nox4 at high concentra-756 Chemistry & Biology 19, 752–763, June 22, 2012 ª2012 Elseviertions of this compound is likely to be an assay artifact, and it can
be concluded that this series of inhibitors does not in general
inhibit Nox4. Some compounds showed differences in selectivity
between Nox1 and Nox2, which probably reflects different inter-
actions with the homologous but not identical bis-SH3 domains
of NoxO1 and p47phox. Nox5 activity depends on calcium
binding (Banfi et al., 2001), phosphorylation (Jagnandan et al.,
2007), and binding of its EF hand to its DH domain (Tirone
et al., 2010), all of which are potential targets for these com-
pounds; other unknown mechanisms also cannot be excluded.
The overall trend for selectivity of these compounds is Nox2 R
Nox1 > Nox5 >> Nox4.
Effect of Ebselen on Membrane Translocation
of p47phox and p67phox
In intact neutrophils, activation of cells with phorbol esters
results in the translocation of p47phox and p67phox to the
plasma membrane, a process triggered by the binding of the
p47phox bis-SH3 domain to the PRD of p22phox (Sumimoto
et al., 1996). The p67phox protein is associated in a complex
with p47phox, which results in its association with themembrane
in parallel with p47phox (de Mendez et al., 1996). This assembly
results in activation of the Nox2 subunit to produce superoxide in
an NADPH-dependent manner. The above results predicted that
ebselen should block the association of p47phox and p22phox,
thereby preventing translocation of p47phox and p67phox
protein to the plasma membrane. As shown in Figure 5, treat-
ment of neutrophils with phorbol 12-myristate, 13-acetate
(PMA), followed by isolation of plasma membranes, induced
a marked increase in the amount of both proteins associated
with the plasma membrane (lane 2). Ebselen had no effect
on translocation in the absence of PMA (lane 3), but completely
blocked PMA-stimulated protein translocation (lane 4). p22phox,
an integral membrane protein, is shown as a gel loading control.
Ebselen at the same concentration did not affect protein-kinase-
C-mediated phosphorylation of p47phox or indeed other neu-
trophil proteins (Figure S3), although it did affect the ability of
p67phox to coimmunoprecipitate with p47phox (Figure S4).
Thus, ebselen prevents the assembly of regulatory subunits
induced by phorbol ester, consistent with its targeting of the
PRD-binding site within the bis-SH3 domain of p47phox.
DISCUSSION
The assembly of a functional Nox2 complex requires the interac-
tion between p47phox and the PRD of p22phox. In an effort to
find inhibitors that are selective for Nox2, we developed an FP
assay based on interrupting this interaction and used it to screen
compounds in a HTS format. Surprisingly, the HTS identified
ebselen and the closely related sulfur-containing analog Thr101.
The evidence presented here demonstrates that ebselen and its
analogs inhibit Nox2 activity by interrupting the binding of the
bis-SH3 domain of p47phox to the PRD of p22phox. While inhi-
bition of NADPH oxidase activity by ebselen was previously
reported (Cotgreave et al., 1989; Wakamura et al., 1990), its
mechanism of action remained obscure and it was generally
thought that inhibition was due to antioxidant properties of the
compound and/or inhibition of upstream signaling. Ebselen
analogs inhibit the activity of native neutrophil Nox2 in purifiedLtd All rights reserved
Table 1. EC50 Values of Ebselen Analogs for Inhibition of Activity, and Control Assays
Assays testing the effects of compounds on the activity of Nox1, Nox2, Nox4, and Nox5 in whole cells (along with assay controls) were performed as
described in Experimental Procedures.
ns, no significant inhibition.
PCT Int. Appl. No. PCT/US2010/056692, Publication No.WO2011062864A2 (publishedMay 26, 2011). Lambeth, David; Smith, SM.; Kawahara, T;Min,
J; Snyder, J P; Sun, A; Ganesh, T.
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Ebselen Blocks Nox2 Assembly and ROS Productionmembrane fractions (Figure 2); such fractions produce ROS only
when supplemented with p47phox, p67phox, and Rac (Uhlinger
et al., 1992). Inhibition of Nox2 activity correlates strikingly with
inhibition of rho-PRD binding to p47-bis-SH3 (Figure 3). Ebselen
analogs inhibit Nox2 activity in intact neutrophils, which requires
p47phox binding to p22phox, at about the same concentration at
which they inhibit binding. Because of the homology between
the Nox2 cytoplasmic proteins and those of Nox1 and Nox3,
ebselen and its analogs are likely to perturb the assembly of
these enzyme complexes similarly to Nox2. Consistent with
this prediction, in studies using cells co-transfected with Nox1,
NOXO1, and NOXA1, ebselen and several congeners inhibited
Nox1 with potencies only somewhat lower than they inhibit
Nox2 (Table 1). On the other hand, ebselen analogs inhibit
Nox5 with an average of 5-fold or lower potency than they
inhibit Nox2, and fail to inhibit the p47phox-independent isoform
Nox4 at concentrations below 10 mM (Figure 4 and Table 1).
Indeed, apparent inhibition above this concentration appears
to be due to interference with the assay itself rather than trueChemistry & Biology 19,inhibition of Nox4. Finally, we showed that ebselen inhibits the
translocation of p47phox and p67phox in PMA-activated human
neutrophils, consistent with the proposed mode of action.
Ebselen as well as a sulfur-containing analog was pre-
viously reported to inhibit superoxide generation from guinea
pig alveolar macrophages at 20 mM, and inhibition was proposed
to be an effect on protein kinase C (PKC) (Leurs et al., 1989;
Wakamura et al., 1990). Ebselen has been shown to inhibit puri-
fied PKC enzyme at submicromolar concentrations (Cotgreave
et al., 1989) but the effect of ebselen on both protein phosphor-
ylation and superoxide generation in intact neutrophils have
reported IC50s in the range of 20–50 mM (Cotgreave et al.,
1989). Inhibition of PKC inhibits phosphorylation of some sites
on p47phox, which in turn should inhibit translocation and
assembly of the Nox2 complex. The concentration of ebselen
used in the translocation experiment shown in Figure 5 is lower
than the IC50 reported by Cotgreave et al. (Cotgreave et al.,
1989) for PKC inhibition in intact cells, and as demonstrated in
Figure S3, this concentration does not affect PKC-mediated752–763, June 22, 2012 ª2012 Elsevier Ltd All rights reserved 757
Figure 5. Ebselen Inhibits Translocation of p47phox and p67phox in
PMA-Stimulated Human Neutrophils.
Human neutrophils were treated with combinations of DMSO vehicle, 500 nM
PMA, and 10 mMebselen as described in Experimental Procedures. Cells were
broken by sonication and separated into cytosol and plasma membrane
fractions as described in Experimental Procedures. Proteins were extracted
from plasma membrane (Lanes 1–4) or cytosol (lane 5) by boiling in Laemmli
sample buffer and separated by SDS-PAGE. After electrophoretic transfer
to low-fluorescence polyvinylidene fluoride membrane, membranes were
probed with antibodies to p22phox, p47phox, and p67phox as described in
Experimental Procedures. Samples were from neutrophils treated as indi-
cated; lane 5 contains protein from untreated neutrophil cytoplasm. The blot
shown is representative of three independently isolated batches of neutro-
phils. Densitometry was performed and analyzed as described in Experimental
Procedures; data shown is the mean fluorescence of p47phox or p67phox in
neutrophil membranes normalized to p22phox from the same treatment, ± SD,
obtained from blots from 3 independently isolated batches of neutrophils.
Figure S3 shows that 10 mM ebselen does not inhibit PKC phosphorylation,
while Figure S4 shows that 10 mM ebselen diminishes the co-immunoprecip-
itation of p67phox with p47phox.
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together, these data indicate that ebselen has a major effect
on the interaction between p47phox and p22phox.758 Chemistry & Biology 19, 752–763, June 22, 2012 ª2012 ElsevierEbselen has been previously reported to decrease oxidative
damage in tissues by reducing hydrogen peroxide (H2O2) and
other hydroperoxides via its glutathione peroxidase catalytic
activity (Schewe, 1995). The reaction, which depends on the
selenium moiety, oxidizes glutathione or other sulfur-containing
substrates (e.g., cysteine, dithioerythritol, dihydrolipoate, etc.)
and reduces hydroperoxides to water or an organic alcohol in
a series of chemical reactions that regenerate the original orga-
noselenium compound (Schewe, 1995). The optimum concen-
tration of ebselen needed to catalyze H2O2 peroxidase activity
is about 20 mM (Mu¨ller et al., 1984). Based on these studies, it
has generally been assumed that ebselen diminishes ROS levels
through this mechanism. However, the present studies docu-
ment that ebselen and its analogs, which include those that
contain sulfur rather than selenium, function to inhibit ROS
generation in neutrophils at concentrations up to two orders of
magnitude lower than those required to observe significant thiol
peroxidase activity.
Previous studies have yielded different potencies of ebselen
on ROS production in various systems. Superoxide generation
in the presence of ebselen was measured in Kupffer cells using
cytochrome c reduction, yielding an IC50 of about 10 mM; in the
same cells, ebselen inhibited nitric oxide generation measured
by conversion of oxyhemoglobin to methemoglobin with an
IC50 of about 3 mM (Wang et al., 1992). When luminol lumines-
cence was used as a report of reactive oxygen, ebselen inhibited
with an IC50 of about 1 mM, demonstrating that assay sensitivity
can affect the results (Wang et al., 1992). In guinea pig neutro-
phils and membranes isolated from these cells (Wakamura
et al., 1990), and in human neutrophils (Cotgreave et al., 1989),
superoxide generation measured using several different
methods was inhibited by both selenium- and sulfur-containing
analogs of ebselen at concentrations similar to those that were
effective in the present studies. The authors in the latter two
studies suggested that in addition to possibly affecting protein
kinase C, these compounds might have a direct effect on the
phagocyte NADPH oxidase. However, the site of action was
not further characterized. In contrast, the inhibition reported in
guinea pig macrophages (Leurs et al., 1989) was at an IC50 of
about 20 mM. The difference between our results in human
neutrophils and those obtained in guinea pig macrophages
may have resulted from cell type or species differences and/or
differences in the assays used. The present studies are in agree-
ment with theWakamura (Wakamura et al., 1990) and Cotgreave
(Cotgreave et al., 1989) studies, which used several methods of
superoxide detection, increasing the confidence in the results.
Our studies also demonstrate that a major site of action of
ebselen and its analogs is the interaction between the bis-SH3
domain of p47phox and the PRD of p22phox.
Previous studies that used peptides based on the PRD of
p22phox demonstrated binding of the peptides to p47phox
(Shi et al., 1996; Dahan et al., 2002), yet these peptides did not
inhibit Nox2 activity in a cell-free system, presumably because
they did not compete effectively with native p22phox in the
membrane for binding. The results reported here used small
molecules which would presumably have better access to the
binding surface, and also lower likelihood of factors such as
conformational restrictions and nonspecific binding to other
surfaces which complicate working with peptides.Ltd All rights reserved
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analogs can affect multiple targets both by direct effects on
the enzymes themselves and by indirect effects such as the
consumption of hydrogen peroxide or lipid peroxides that serve
as substrates for certain enzymes. Ebselen and its analogs also
inhibit endothelial nitric oxide synthase, lipoxygenases, c-Jun
N-terminal kinase and horseradish peroxidase (Zembowicz
et al., 1993; Shimohashi et al., 2000; Schewe et al., 1994; Mishra
et al., 2006). In the case of lipoxygenase, inhibition results from
depletion of the lipid peroxide substrate by the peroxidase-like
activity of ebselen (Tabuchi et al., 1995), while in other cases,
the mechanism is less clear. For example, ebselen inhibits
horseradish peroxidase with an IC50 of 17 mM by a mechanism
that does not correlate with its glutathione peroxidase activity
and in a manner that is independent of a thiol donor (Mishra
et al., 2006). In this light, our data indicating that ebselen inhibits
co-immunoprecipitation of p67phox with p47phox in PMA-
stimulated cells (Figure S4) do not discriminate whether this a
direct effect of ebselen on the interaction between theC-terminal
PRD of p47phox and the C-terminal SH3 domain of p67phox, or
whether it is caused by an indirect effect such as an allosteric
effect resulting from binding to the bis-SH3 domain of p47phox.
Whether ebselen binds to single SH3 domains as opposed to the
bis-SH3 domain is a topic for further studies.
The complex chemistry associated with the selenium center
in ebselen increases the likelihood that the compound can act
by several mechanisms. The mode of action we describe here
does not conflict with or rule out other known or proposed
modes of action. Ebselen’s glutathione peroxidase activity has
been extensively studied, and certainly could contribute to
the inhibition of Nox2-dependent H2O2 production when the eb-
selen concentration is above 10 mM. In some enzymes, ebselen
can modify cysteine residues (Ouertatani-Sakouhi et al., 2010).
Our binding assay used a recombinant construct consisting of
only the bis-SH3 domain of p47phox and a synthetic peptide
based on the PRD of p22phox. Inspection of a published
structure of p47phox in complex with the PRD peptide of
p22phox (Groemping et al., 2003) reveals that the sole cysteine
in the p47-bis-SH3 domain points away from the binding groove
and does not participate directly in the binding of the PRD. We
performed preliminary in silico docking of ebselen into this
crystal structure, where it fits with favorable binding energy
(data not shown) and all low energy poses are distant from
the cysteine. These considerations make it unlikely that cysteine
modification contributes to ebselen’s effects on this interaction.
Nox1, Nox2, and Nox4 have different patterns of accessible
cysteines on their cytoplasmic dehydrogenase domains. In
particular, Nox2 has two cysteines (368 and 370) in proximity,
modification of which might be expected to affect activity.
Nox1 lacks cysteines at homologous positions, yet selenium
and sulfur analogs inhibit Nox1 with micromolar potency. These
data argue against chemical modification of Cys368 and
Cys370 as a major mode of inhibition of Nox2 by these
compounds. Nonetheless, ebselen and analogs might modify
cysteines in other regions of the Nox1 or Nox2 complex,
contributing to inhibition. Because sulfur analogs of ebselen
are poorly reactive with free cysteines (Leurs et al., 1989), their
ability to inhibit Nox1 and Nox2 cannot be ascribed to that
mechanism. Our results suggest that many effects, includingChemistry & Biology 19,anti-inflammatory effects, that were previously ascribed to eb-
selen’s antioxidant activity (Parnham and Graf, 1987) are likely
instead to be the result of ebselen’s direct inhibition of Nox1
and Nox2 activity by preventing assembly and activation of
the Nox1 and Nox2 complexes.SIGNIFICANCE
NADPH oxidases (Nox/Duox enzymes) are a primary source
of reactive oxygen species (ROS), which function in normal
physiology in diverse cell types and, when overproduced,
in pathophysiology. The Nox2 isoform is implicated in
a variety of inflammatory and neurodegenerative conditions.
Recent genetic studies using Nox2-deleted mice identify
this enzyme as a novel target for treatment of several
diseases. Nox2 enzyme function requires the assembly
of a complex consisting of the membrane-bound Nox2-
p22phox heterodimer and cytosolic protein factors. The
binding of the proline-rich domain of p22phox to the bis-
SH3 domain of p47phox is a crucial step in this assembly.
A fluorescence polarization assay that monitors this binding
was developed and used in a high-throughput. The screen
identified ebselen, previously characterized as a glutathione
peroxidase mimetic, and several of its analogs, as inhibitors
of this binding interaction. Ebselen and its analogs also
potently inhibited superoxide generation in human neutro-
phils and in a Nox2 cell-free system, with IC50 values well
below the10 mM concentration at which ebselen functions
as a glutathione peroxidase mimetic. Medicinal chemistry
was performed to explore structure-activity relationships
and to increase potency. Nox2 inhibition requires isothia-
zol-3(2H)-one (sulfur) or selenazol-3(2H)-one (selenium),
and moieties such as carboxymethyl or 1,3 dioxane ap-
pended to the nitrogen of the phenyl ring in the sulfur series
increased potency. Ebselen blocked the phorbol ester-
activated translocation of p47phox and p67phox to neutro-
phil membranes, which requires the same interaction
monitored by the fluorescence polarization assay. Neither
selenium nor sulfur analogs of ebselen inhibited Nox4,
which does not require activating subunits and which
produces hydrogen peroxide. These results effectively rule
out peroxidase mimetic activity as the primary mode of
Nox2 inhibition by these compounds. Thus ebselen and its
analogs represent a class of compounds that inhibit ROS
generation by interrupting the assembly of Nox2-activating
regulatory subunits.EXPERIMENTAL PROCEDURES
Materials
Chemicals and enzymes were purchased from Sigma (St. Louis, MO)
unless otherwise indicated. Rhodamine-labeled peptide with the sequence
Rhodamine-PPTNPPPRPPAE-amide (residues 151-162 of mouse p22phox)
was synthesized by the Emory University Microchemical Facility. The peptide
was dissolved in water and stored at 80C. Ebselen was purchased from
Calbiochem EMD Chemicals (Gibbstown, NJ). Thr101 was purchased from
Chem Div, Inc. Compounds were dissolved in DMSO at a stock concentration
of 10 mM and stored at 20C. Antisera against p67phox and p47phox were
the generous gifts of Dr. Mark Quinn, University of Montana, and Dr. Jamal
El-Benna, INSERM, Paris.752–763, June 22, 2012 ª2012 Elsevier Ltd All rights reserved 759
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Thr101 analogs (isothizol-3-ones) were synthesized following a reported
protocol (Correa et al., 2006) starting from commercially available methyl
2-mercaptobenzoate, and substituted methyl-2-marcaptobenzoates (see Fig-
ure S2). Synthesis of ebselen and its derivatives was performed as described
previously (Chang et al., 2003). Characterization data for representative
members are provided in supporting information.
Cloning and Expression of Recombinant Proteins
The cDNA encoding the bis-SH3 domain of human p47phox (residues
156–285) was obtained by polymerase chain reaction and subcloned into
pGEX4T3 (GE Life Sciences, Piscataway, NJ) in frame with an N-terminal
GST protein that was used as a purification tag. The C terminus of human
p22phox (residues 132–195, which includes the PRD) was obtained by PCR
and subcloned into pMALc2x (NEB, Ipswich, MA) in frame with an N-terminal
MBP that was also used as a purification tag. GST, GST-tagged p47phox-bis-
SH3 domain (GST-p47-bis-SH3), MBP, and MBP-tagged p22phox C terminus
(MBP-p22-C) were expressed in and affinity purified from Escherichia coli
BL21 cells using glutathione agarose for GST-tagged proteins or amylose resin
for MBP-tagged proteins, according to the instructions of each plasmid
vendor. Proteins were eluted in 20 mM TrisHCl pH 7.5, 150 mM NaCl, 1 mM
EDTA supplemented with glutathione or maltose as appropriate, dialyzed
overnight against 20 mM HEPES pH 7.5, 25 mM NaCl, and stored at 80C
until use. Protein concentrations were determined using the BCA method
(Pierce Thermo Scientific, Rockford, IL) according to the manufacturer’s
instructions. Proteins were >90% pure as assessed by SDS-PAGE followed
by Coomassie Blue staining (data not shown).
Cell-Free Assay for Nox2-Dependent Superoxide Generation and
Xanthine/Xanthine Oxidase Control Assay
Plasma membranes were prepared from human neutrophils as described
previously (Curnutte et al., 1987) and stored at 80C until use. Superoxide
generationwasassayedaspreviouslydescribed (Ritsick et al., 2007)withminor
modifications. Briefly,membranes containing 0.3mgof proteinweremixedwith
0.25 mg p67Np47N fusion protein (human p67phox residues 1–210 fused to
human p47phox residures 1-286, (Ebisu et al., 2001), 0.2 mg Rac1Q61L,
500 nM FAD, 50 mM L-012 (Wako Chemicals, Richmond, VA), and varying
concentrations of ebselen or analogs (dissolved in DMSO) in 100 ml of assay
buffer (100 mM PIPES, 30 mM NaCl, 35 mM MgCl2, 1M KCl, pH 7.4); DMSO
concentration was kept constant at 1%. We used reported literature values
of Nox2 content of human neutrophils (Parkos et al., 1987; Quinn et al., 1993)
to calculate that this assay includes approximately 0.1 pmol of Nox2 catalytic
subunit; the recombinant proteins are in excess (9.1 pmol for Rac1Q61L and
5.2 pmol for p67-p47 chimera). The optimal NADPH concentration (10 mMfinal)
was determined empirically, and avoided a quenching artifact seen at higher
substrate concentrations. NADPH was added and luminescence was
recorded in a Synergy 2 microplate reader (Biotek Instruments, Winooski,
VT). After 2 minutes, 90 mM sodium dodecyl sulfate (SDS) was added and
luminescence was recorded for an additional 20 min. Maximum luminescence
was obtained in 3–5min, and is reported as themean from 3–5 determinations.
In all cases, luminescence of incubations with the general Nox inhibitor diphe-
nylene iodonium (DPI) was less than 10% of that from incubations containing
DMSO vehicle alone, consistent with Nox2 as the source of the ROS signal
(data not shown). In assay control experiments, 1 mM xanthine oxidase re-
placed the Nox2 system as the source of superoxide. Xanthine (50 mM) was
added to initiate the reaction and luminescence was recorded for 20 min.
Measurement of ROS Generation in Whole Cells
Neutrophils were isolated from blood collected from human volunteers
as previously described (Curnutte et al., 1987) in accordance with Emory
University IRB guidelines. Nox2 activity was assessed using luminescence
from L-012; 104 freshly isolated human neutrophils were suspended in
100 ml assay buffer to which 50 mM L-012, along with DMSO, 10 uM DPI, or
varying concentrations of compound were added. The final DMSO was
maintained constant in all samples at 1%. After 2 min, 400 nM (final con-
centration) of phorbol 11-myristate 12-acetate (PMA) was added, and lumines-
cencewas recorded for 20min using a Synergy 2microplate reader. Maximum
luminescence, which was achieved before 5 min, was calculated from the
average of 3-5 consecutive points. In all cases, luminescence fromDPI-treated
cells was less than 10% of that from DMSO-treated cells, consistent with
a Nox enzyme as the source of ROS (data not shown).760 Chemistry & Biology 19, 752–763, June 22, 2012 ª2012 ElsevierHEK cells stably transfectedwith Nox1 (HEK/Nox1rb) or Nox4 (HEK/Nox4rb)
were the generous gift of Dr. Ralf Brandes (Goethe University, Frankfurt,
Germany). 106 HEK, HEK/Nox1rb, or HEK/Nox4rb cells were plated on
10 cm culture plates, incubated for 24–48 hr in supplemented medium and
harvested as previously described (Cheng et al., 2004). Twenty-four hours
after plating, HEK cells were transiently transfected with 6 mg of eukaryotic
expression plasmid containing Nox5 (Kawahara et al., 2011), or HEK/Nox1rb
cells were transiently transfected with 1.5 mg of eukaryotic expression plasmid
containing NoxO1 and 1.5 mg plasmid containing NoxA1 (Cheng and Lambeth,
2004), per 10 cm plate, using the Fugene (Roche, Indianapolis, IN) system
according to the manufacturer’s instructions; transiently transfected cells
were incubated for an additional 24 hr. Cells were washed and resuspended
in phosphate-buffered saline (PBS) (11.9 mM phosphate, 137 mM NaCl,
2.7 mM KCl, pH 7.4) supplemented with 1% glucose. L-012 luminescence
was assayed essentially as previously described for neutrophils, except that
105 transfected HEK cells were used in a final reaction volume of 111 ml; for
HEK cells transiently transfected with Nox5 the reaction mixture was supple-
mented with calcium and ionomycin (Kawahara et al., 2011); and for HEK/
Nox4rb cells the reaction mixture was supplemented with 0.9 units/ml (final)
of horseradish peroxidase. In Nox4 assay control experiments, 25 mM H202
replaced stably transfected HEK cells. The xanthine/xanthine oxidase assay
described above served as the assay control experiment for HEK cells trans-
fected with Nox1 and Nox5.
Assessment of Cell Viability
Freshly isolated human neutrophils (5 3 104 cells) were suspended in PBS
supplementedwith 1%glucose, or 43 104 HEK/Nox4rb cells were suspended
in DMEM supplemented with 10% FBS, and incubated with varying amounts
of compound or DMSO vehicle for 10 min at 37C, then assayed for viability
using the CellTiterGlo kit (Promega) according to the manufacturer’s instruc-
tions. This kit determines the proportion of viable cells based on luminescent
quantification of ATP, an indicator of metabolic activity. Data were normalized
to 0% viable cells with 1% Triton X-100, a potent detergent that interrupts cell
integrity, as suggested by the manufacturer.
Fluorescence Polarization Assay
Assays were performed in black, flat-bottom 384 well microplates (Corning,
Corning, NY) in FP buffer (10 mM HEPES, pH 7.4; 150 mM NaCl; 0.01%
Tween-20) using a final volume of 50 ml at room temperature. Parallel and
perpendicular fluorescence intensities were measured using excitation filter
545 (bandwidth 40) nm and emission filter 620 (bandwidth 40) nm in a Synergy
2 fluorescencemicroplate reader, and FP values were calculated by themanu-
facturer’s Gen5 software. To establish feasibility, we measured the FP of
10 nM of rhodamine-labeled peptide corresponding to the PRD domain of
p22phox (rho-PRD) in the presence of a range from 0 to 3 mM protein (either
GST alone or GST-p47-bis-SH3). The isolated bis-SH3 domain of p47phox
is in the open state (without the need for phosphorylation) because it lacks
the autoinhibitory domain of the native protein (Yuzawa et al., 2004). Pre-
liminary experiments (not shown) revealed that the binding was somewhat
tighter and more stable with the peptide based on the mouse PRD sequence.
We therefore used mouse PRD in the HTS. To demonstrate the validity of the
assay, we also measured FP of 10 nM rho-PRD, plus GST-p47-bis-SH3
(20–40 nM) in the presence of increasing concentrations of MBP or MBP-
p22-C. The stability of the assay was evaluated by recording FP values at inter-
vals ranging from 1 to 24 hr. The assaywas also carried out at a range of DMSO
concentrations up to 5% to investigate the sensitivity to solvent.
For competition experiments, the FP of 10-20 nM rho-PRD plus GST-p47-
bis-SH3 (20–40 nM) was recorded before and after addition of either MBP-
p22-C (500 nM) or varying concentrations of compound (DMSO concentration
was adjusted to 1% final). The FP of the free rho-PRD peptide alone in FP
buffer was also recorded. To ensure that a stable signal had been achieved,
FP was measured at several intervals over a total period of 60 min. Values at
the 30 min time point were used.
Pull-Down Assay
In oneml of FP assay buffer, 1.2 nmoles of GST-p47-bis-SH3was incubated at
room temperature for 1 hr with 1.2 nmoles of MBP-p22-C in the presence and
absence of DMSO vehicle, 20 mM ebselen, or 10 mM rho-PRR. Control incuba-
tions using combinations of purifiedGST, purifiedMBP,MBP-p22-C, andGST-
p47-bis-SH3 were carried out in the same conditions. Glutathione agarose
beads were added, incubated for another hour at room temperature, washed,Ltd All rights reserved
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glycerol, 10% 2-mercaptoethanol, 0.004% bromphenol blue and 0.125 M Tris
HCl, pH 6.8). Samples containing equal of GST orGST- p47-bis-SH3were sub-
jected to SDS-PAGE and visualized by staining with Coomassie Blue.
Translocation of p47phox and p67phox
Neutrophils (108 cells) in 3.25 ml assay buffer containing 0.1% DMSO with or
without 10 mM ebselen were incubated at 37C. After 2 min, 500 nM PMA or
vehicle control was added; final DMSO was kept constant in all samples at
0.2%. Cells were incubated at 37 C for 10 min, and pelleted by centrifuging
for 10min at 300 xg. Plasmamembraneswere isolated fromhumanneutrophils
as previously described (Curnutte et al., 1987). An aliquot of each membrane
samplewasassayed for protein concentrationby theBCAmethod; total protein
was extracted from the remainder of the membranes by boiling for 10min in 2x
Laemmli sample buffer. Protein from each sample was loaded onto a 4%–15%
TGX gel and subjected to SDS-PAGE. Western blotting was carried out
following the protocol suggested by Li-Cor (Li-Cor Biosciences, Lincoln, NB).
Blots were probed with either a mixture of antiserum to p47phox and mono-
clonal antibody to p67phox or with monoclonal antibody to p22phox (Abcam,
Cambridge, MA). Protein bands were detected by addition of appropriate Li-
Cor fluorescence-tagged secondary antibodies to mouse or rabbit IgG and
visualized using a Li-Cor Odyssey imager. Bands were sized and images
were subjected to densitometry using the vendor’s software.
Detection of PKC-Mediated Phosphorylation of p47phox
and Co-Immunoprecipitation of p67phox with p47phox
In 1 ml Hank’s buffer containing 1%DMSOwith or without 10 mM ebselen, 108
neutrophils were incubated at 37C. After 2min, 500 nMPMAor vehicle control
was added; final DMSO was kept constant in all samples at 2%. Cells were
incubated at 37C for 15 min, at which time 10 ml ice-cold PBS was added to
stop the stimulation. Cells were treated with 2.7 mM DFP and resuspended in
1 ml of ‘‘RIPA + 11’’ buffer (50 mM Tris pH 7.4, 150 mMNaCl, 0.1% Na-deoxy-
cholate, 0.1%NP-40) supplementedwith complete protease and phosphatase
inhibitors (Roche, Indianapolis, IL), 0.5 mg/ml b-glycerol phosphate, 0.5 mg/ml
p-nitrophenyl phosphate, and 0.2mg/ml levamisol. The lysateswere sonicated
briefly and centrifuged at 100,000 x g for 20 min. Rabbit polyclonal p47phox
antibodywas used to immunoprecipitate p47phox using standard immunopre-
cipitation and western blotting methods. For assessing PKC-mediated serine
phosphorylation, blots were probed with rabbit antibody to phosphoserine in
a PKC- motif (Cell Signaling Technology, Beverly, MA). To detect p47phox
and p67phox in the immunoprecipitates and lysates the blots were probed
with rabbit polyclonal antibody to p47phoxor p67phox respectively. Secondary
antibodies included ImmunoCruz HRP-conjugated antibodies (Santa Cruz
Biotechnology, Santa Cruz, CA) to avoid heavy chain interference in the
immunoprecipitates, or standard hrp-goat-anti-rabbit or anti-mouse anti-
bodies (BioRad Hercules, CA). Blots were visualized using SuperSignal chem-
iluminescence reagent kit (ThermoScientific, Rockford, IL) according to the
manufacturer’s instructions. To normalize samples, the blots were stripped
and probed with mouse monoclonal antibody to actin (Sigma, St. Louis, MO).
Curve-Fitting and Statistical Analysis
Data analysis was performed using Prism 4 software (GraphPad Software, La
Jolla, CA). Data for binding was fit to a 4-parameter nonlinear least-squares
sigmoidal dose response model, in which parameters are: maximum and
minimum polarization values, EC50 values, and slope of the curve. Data for
inhibition of binding, or for inhibition of activity, were fit to a one-site competi-
tion model that uses a nonlinear least-squares fit and which reports IC50, Kd,
and Ki values. Densitometry values of p47phox or p67phox bands in westerns
were compared by first determining total intensity for the p47phox, p67phox
bands, or p22phox bands across all four experimental treatments. The inten-
sity of each band was normalized as the fractional intensity of the band in each
treatment to the total intensity of the protein detected across all treatments.
P47phox and p67phox intensities were normalized to the intensity of the
p22phox band from the same treatment. Normalized intensities were com-
pared by one-way ANOVA.
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